OverviewZogenix, Inc. (Nasdaq: ZGNX) is a pharmaceutical company committed to developing and commercializing CNS therapies that address specific clinical needs for people living with orphan and other CNS disorders who need innovative treatment alternatives to improve their daily functioning.
NASDAQ | ZGNX (Common Stock)
$9.35 + 0.25
Data as of 10/21/16 4:00 p.m. ET
Data provided by Nasdaq. Minimum 15 minutes delayed.
Investor Events More
Wednesday, September 28, 2016 10:00 a.m. ET
Zogenix, Inc. at LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology
Tuesday, September 27, 2016 4:00 p.m. ET
Zogenix, Inc. at Ladenburg Thalmann 2016 Healthcare Conference